FARESTON

LOE Approaching

toremifene citrate

Kyowa Hakko Kirin
NDAORALTABLET
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly…

Indications (3)

metastatic breast cancer in postmenopausal women with estrogen-receptor positiveunknown tumorsbreast cancer

Clinical Trials (1)

NCT01214291Phase 3Withdrawn

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

Started Mar 2011
0
Risk of Bone Fracture Occurrences
Company
Kyowa Hakko Kirin
Kyowa Hakko Kirin
CA - La Jolla
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers